2,8-Diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine potent CCR4 antagonists capable of inducing receptor endocytosis by Shukla, Lena et al.
Shukla, Lena and Ajram, Laura A. and Begg, Malcolm and Evans, Brian 
and Graves, Rebecca H. and Hodgson, Simon T. and Lynn, Sean M. and 
Miah, Afjal H. and Percy, Jonathan M. and Procopiou, Panayiotis A. and 
Richards, Stephen A. and Slack, Robert J. (2016) 2,8-
Diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine potent CCR4 antagonists 
capable of inducing receptor endocytosis. European Journal of 
Medicinal Chemistry, 115. pp. 14-25. ISSN 0223-5234 , 
http://dx.doi.org/10.1016/j.ejmech.2016.02.058
This version is available at http://strathprints.strath.ac.uk/57543/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (http://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any correspondence concerning this service should be sent to the Strathprints administrator: 
strathprints@strath.ac.uk
The Strathprints institutional repository (http://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research 
outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the 
management and persistent access to Strathclyde's intellectual output.
1 
 
2,8-Diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine Potent CCR4 Antagonists Capable of 
Inducing Receptor Endocytosis. 
Lena Shukla,a Laura A. Ajram,b Malcolm Begg,b Brian Evans,a Rebecca H. Graves,c Simon 
T. Hodgson,a Sean M. Lynn,d Afjal H. Miah,*a Jonathan M. Percy,e Panayiotis A. 
Procopiou,*a Stephen A. Richards,d  and Robert J. Slackb 
a Department of Medicinal Chemistry,  
b Department of Respiratory Biology, 
 c Department of Drug Metabolism and Pharmacokinetics,  
Respiratory TAU, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, 
Stevenage, Hertfordshire, SG1 2NY, United Kingdom, 
d UK Analytical Chemistry, Platform Technology & Science, GlaxoSmithKline Medicines 
Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, United Kingdom 
e WestCHEM Department of Pure and Applied Chemistry, University of Strathclyde, 295 
Cathedral Street, Glasgow, G1 1XL, United Kingdom. 
 
* To whom correspondence should be addressed. Phone: (+44)1438 762883.  Fax: (+44)1438 
768302.  E-mail: pan.a.procopiou@gsk.com 
2 
 
Abstract 
A number of potent 2,8-diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine CCR4 antagonists  
binding to the extracellular allosteric site were synthesised.  (R)-N-(2,4-Dichlorobenzyl)-2-(2-
(pyrrolidin-2-ylmethyl)-2,8-diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine (R)-(18a) has high 
affinity in both the [125I]-TARC binding assay with a pKi of 8.8, and the [35S]-GTPJS 
functional assay with a pIC50 of 8.1, and high activity in the human whole blood actin 
polymerisation assay (pA2 = 6.7).  The most potent antagonists were also investigated for 
their ability to induce endocytosis of CCR4 and were found to internalise about 60% of the 
cell surface receptors, a property which is not commonly shared by small molecule 
antagonists of chemokine receptors. 
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1. Introduction 
Chemokines are a group of about 50 small, basic proteins of 8  10 kDa, which together with 
their receptors mainly regulate the recruitment of leukocytes into inflammatory sites.  
Chemokines exert their effects through the activation of G protein-coupled receptors situated 
on the cell surface.  Ten CC chemokine receptors have been identified so far named as CC-
chemokine receptor 1, 2, 3 etc.  Most chemokine receptors recognise more than one 
chemokine and several chemokines bind to more than one receptor.1  CC chemokine receptor 
4 (CCR4) is the only receptor identified so far for the macrophage-derived chemokine (MDC, 
CCL22) and thymus and activation-regulated chemokine (TARC, CCL17), and shown to be 
highly expressed in the thymus.  T helper 2 (Th2) cytokines in inflamed tissues lead to 
eosinophilia, high levels of serum IgE and mast cell activation, all of which contribute to the 
pathogenesis of allergic diseases.2  Upon exposure to allergen, dendritic cells within tissue 
secrete CCL22 and CCL17, which can recruit Th2 cells from the circulation.  The T cells can 
then migrate along this chemokine gradient to the dendritic cells.  The latter migrate from the 
inflamed tissue to local lymph nodes where CCL22 and CCL17 may recruit further T cells.  
Elevated levels of CCL17 and CCL22 as well as accumulation of CCR4-positive cells were 
observed in lung biopsy samples from patients with atopic asthma following allergen 
challenge.3  CCR4 is also expressed by immune suppressive regulatory T cells,4,5 and a minor 
subset of Th17 cells.6,7  Hence CCR4 antagonists represent a novel therapeutic intervention in 
diseases where CCR4 is involved, such as asthma,8 lung disease,4 atopic dermatitis,9 allergic 
bronchopulmonary aspergillosis,10 leukemia,11 colon cancer,12 inflammatory bowel disease,5 
the mosquito-borne tropical diseases, such as Dengue fever,13 and allergic rhinitis.14  In 
addition, CCR4 antagonists were used as molecular adjuvants in vaccines.15-18  Finally, CCR4 
monoclonal antibodies were recently explored for CCR4+ T cell leukemia and one such 
antibody, Mogamulizumab (20 mg injection), was launched in 2012 in Japan for the 
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treatment of relapsed or refractory adult T cell leukemia/lymphoma.19,20  In December 2014 
approval for additional indication for chemotherapy-native CCR4-positive adult T-cell 
leukemia-lymphoma (ATL) of Mogamulizumab was granted in Japan.  The launch of the 
humanised monoclonal antibody Mogamulizumab underlines the value of generating cheaper 
small molecule CCR4 antagonists in this area.  Progress in the discovery of small-molecule 
CCR4 antagonists was reviewed by Purandare and Somerville in 2006.21  A number of other 
CCR4 antagonists have appeared in the literature since the publication of this review.22-38  
These antagonists appear to belong to two chemotypes.  The first chemotype, exemplified by 
compounds 1 ± 7, includes lipophilic amines, such as Bristol Myers Squibb (BMS) 
compounds 122 and 2,24 Astellas compounds 327 and 4,29 the Daiichi Sankyo compound 5,31 
633 and 7.34  The second chemotype, exemplified by sulfonamides 8 ± 10, includes 
AstraZeneca pyrazine 8,35 the Ono pyrazine 9,36 and the GlaxoSmithKline indazole 1037,38 
(Fig. 1).  Indazole 10 was the first small molecule candidate to be progressed to human 
studies; however, the compound suffered from low solubility and weak potency.39  Our group 
has recently published our efforts to identify novel sulfonamide templates for lead 
optimisation studies.40,41   
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Figure 1.  Structures for some recently published CCR4 antagonists. Numbers refer to 
compounds described in text. 
Moreover, our group has recently reported that antagonism of human CCR4 can be achieved 
through three distinct binding sites on the receptor.42  Sulfonamides 8 ± 10 were shown to 
bind at an intracellular allosteric binding site, arbitrarily named at GSK as site II, which is 
different from the binding site (site I), where lipophilic amine antagonists, such as 1, 2 and 4 
bind.  Glu 290, which is found in Helix VII, is the anchor point for site I ± perhaps the only 
residue strongly believed to interact with the chemokine, and these basic site I antagonists.  
The two allosteric binding sites I and II are distinct from each other and from the orthosteric 
binding site where CCL17 and CCL22 bind.  Similar findings for a CCR4 and CCR5 
intracellular binding site were reported by the AstraZeneca group.43  Our group has so far 
reported only on sulfonamide (site II) intracellular CCR4 antagonists,37,38,40,41 herein we 
report our efforts on identifying basic site I allosteric antagonists. 
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2. Chemistry 
At the time that this work was initiated X-ray crystal structures of G Protein Coupled 
Receptors were not reported, however, the structures of antagonists 1 ± 3 were published, 
together with a CCR4 homology model based on bovine rhodopsin.27  Our initial lead, the 
spirocyclic pyrimidine proline amide (±)-11a, was overlaid on BMS pyrimidine homoproline 
amide 1 docked in the homology model, and showed that the basic nitrogen atoms of the 
proline and homoproline moieties of (R)-1 and (R)-11a respectively adopted a similar 
position in the receptor, although the proline nitrogen was further away from the core (Fig. 
2). 
 
Figure 2.  Overlay of compound (R)-1 (black) with compound (R)-11a (green). 
Compounds 11a-h were prepared according to the route outlined in Scheme 1 starting from 
2,4-dichloropyrimidine 12 and 2,4-dichlorobenzylamine to give after chromatography the 
regioisomeric chloropyrimidines 13 and 14 in 21 and 49% yield respectively.  The amine was 
expected to react predominantly at the more electrophilic C4-position to give 14 as the major 
regioisomer.  The structure of 14 was confirmed by irradiation of the benzylic NH proton 
(8.42 ppm), which produced an NOE enhancement of the methylene protons (4.54 ppm) and 
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the pyrimidyl proton at the 5-position (6.58 ppm).  The latter compound was reacted with 
commercially available BOC-2,8-diazaspiro[4.5]decane 15 in refluxing isopropyl alcohol to 
give spirocyclic pyrimidine 16 in 90% yield.  The BOC protecting group was removed 
following treatment with hydrogen chloride in dioxane (99%), and the resulting amine 17 was 
acylated with a variety of acids in the presence of N-[(dimethylamino)-1H-1,2,3-triazolo-
[4,5-b]pyridin-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide 
(HATU) in DMF.  In the cases where the acid was a BOC-protected amino acid the resulting 
acylation product was deprotected with TFA to give the target compounds 11a-h.  The 
amides 11a,b were reduced with either lithium aluminum hydride in THF or with borane in 
THF to give the diamines 18a,b.  Alternatively, racemic 18a was obtained from 17 and N-
BOC-2-formylpyrrolidine by reductive amination in the presence of sodium 
triacetoxyborohydride.  The two enantiomers of 18a were resolved by preparative chiral 
HPLC, and characterised by comparison with material obtained from the reduction of the 
enantiomerically pure amides 11a.   
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Scheme 1.  Reagents and Conditions:  a) 2,4-dichlorobenzylamine (1.1 equiv.), DIPEA, 1,2-
dichloroethane, 20 °C, 24 h;  b) 15, isopropyl alcohol, 90 °C, 48 h;  c) 4M HCl in dioxane, 
0.5 h;  d) RCO2H (or BOC-protected amino acid), HATU, DIPEA, DMF, 1 h;  e) TFA, 
dichloromethane (in the case of BOC protected amino acids);  f) LiAlH4, THF, 0 °C, 18 h;  g) 
NaBH(OAc)3, THF. 
 
The racemic 2,4-difluoro analogues of 11a and 18a (22 and 23 respectively) were prepared 
from 12 by analogous synthesis as shown in scheme 2. 
 
Scheme 2.  Reagents and Conditions:  a) 2,4-difluorobenzylamine (1.1 equiv.), DIPEA, 1,2-
dichloroethane, 20 °C, 24 h;  b) 15, isopropyl alcohol, 90 °C, 48 h;  c) 4M HCl in dioxane, 
0.5 h;  d) (±)-N-BOC-proline, HATU, DIPEA, DMF, 1 h;  e) TFA/dichloromethane or neat 
TFA;  f) N-BOC-2-formylpyrrolidine, NaBH(OAc)3, THF, 4Å molecular sieves. 
10 
 
 
Finally, the N-methyl analogues of 11a and 18a (26 and 27 respectively) were prepared from 
12 by a similar route as shown in Scheme 3. 
 
Scheme 3.  Reagents and Conditions:  a) N-methyl-(2,4-dichlorobenzyl)amine (1.1 equiv.), 
DIPEA, 1,2-dichloroethane, 20 °C, 24 h;  b) 15, isopropyl alcohol, 90 °C, 48 h;  c) 4M HCl in 
dioxane, 0.5 h;  d) (±)-N-BOC-proline, HATU, DIPEA, DMF, 1 h;  e) TFA, 
dichloromethane;  f) N-BOC-2-formylpyrrolidine, NaBH(OAc)3.  
 
3. Results and Discussion 
The antagonist activity at human CCR4 of the compounds shown in Table 1 was determined 
by [125I]-TARC radioligand binding assay.44  This assay used recombinant CCR4 expressing 
CHO cell membranes adhered to WGA-coated Leadseeker scintillation proximity assay 
(SPA) beads.  The SPA beads contained scintillants that emit light when stimulated by 
emitted radiation, for example, during binding of the radiolabelled ligand to CCR4 bringing it 
in close proximity to the bead, and the output was measured on a scintillation counter.  The 
[125I]-TARC binding assay measured the inhibition of radiolabelled CCL17 binding directly 
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to CHO-CCR4 membranes in the presence of an antagonist, and the affinity was expressed as 
the pKi.  Another assay using isolated human peripheral blood mononuclear cells (PBMCs) 
was used as a secondary screen to determine potency against the native receptor for the more 
potent compounds in the primary assay.42  The assay quantified cytoskeletal reorganisation 
(formation of filamentous (F-) actin) which occurs in a variety of cells in response to 
chemoattractants and is a prelude to chemotaxis.  This was achieved by staining the F-actin 
with a fluorescent derivative of phalloidin, which binds with high affinity and specificity to 
the interface between actin monomers in F-actin.  The response was measured as an increase 
in the fluorescence intensity of the target cell population in a flow cytometer and was 
expressed as a pA2.  Calculated partition coefficient (clogP), chromatographic logD7.4 (chrom 
logD at pH 7.4) and ChemiLuminescent Nitrogen Detection (CLND) kinetic solubility are 
included for all test compounds in this study.  The high throughput CLND solubility assay 
involved addition of aqueous buffer to a test compound DMSO solution over a period of time 
until the compound precipitated.  Compounds 1 and 9 were used as standards DQGDUH
LQFOXGHGLQ7DEOH 
7KHXQFDSSHGVSLURF\FOLFDPLQHKDGZHDNDIILQLW\S.LFRPSDUHGWRWKHVWDQGDUGV
7KHUDFHPLFSUROLQHDPLGHDZDVWHQ-IROGPRUHSRWHQWWKDQEXWZDVVWLOOZHDNHUWKDQ
WKHUHIHUHQFHFRPSRXQG%RWKHQDQWLRPHUVRIWKHKRPRSUROLQHDQDORJXHEKDGVLPLODU
DIILQLW\WR-DEXWZHUHPRUHOLSRSKLOLFFORJ3FKURPORJ'DQGKDGVLPLODU
VROXELOLW\7KHE-DPLQRDFLGDPLGHVFDQGGKDGVOLJKWO\UHGXFHGDIILQLW\FRPSDUHGWR
-D7KHVHILQGLQJVSDUDOOHOHGWKH6$5UHSRUWHGIRUWKH%06VHULHV7KHVDUFRVLQH
DPLGHHDOWKRXJKOHVVOLSRSKLOLFWKDQWKHDQDORJXHVLQYHVWLJDWHGVRIDUFKURPORJ'
RIIHUHGQRDGGLWLRQDODGYDQWDJHDIILQLW\RUVROXELOLW\7KHF\FORKH[\ODPLGHIKDGWKH
ORZHVWDIILQLW\RIDOOFRPSRXQGVLQ7DEOHORZHVWVROXELOLW\DQGKLJKHVWOLSRSKLOLFLW\FORJ3
DQGFKURPORJ'7KH-S\ULG\ODPLGHJZDVVLPLODUO\GLVDSSRLQWLQJDVLW
12 
 
RIIHUHGQRDGYDQWDJHIRUHLWKHUDIILQLW\RUVROXELOLW\7KHPRUSKROLQHDPLGHKZDVPDGHDV
DOHVVEDVLFDQDORJXHWR-DKRZHYHULWZDVVWLOOOLSRSKLOLFORJ'DQGKDGRQO\
VOLJKWO\LQFUHDVHGVROXELOLW\8QIRUWXQDWHO\WKLVFRPSRXQGZDVQRWWHVWHGLQWKHELQGLQJ
DVVD\7KHGLIOXRURDQDORJXHDOWKRXJKOHVVOLSRSKLOLFWKDQDZDVOLNHWKH1-PHWK\O
DQDORJXHHTXLSRWHQWWRD$OORIWKHDPLGHVGLVFXVVHGVRIDUKDGDWOHDVWWHQ-IROGORZHU
DIILQLW\WKDQDQGZHUHWKHUHIRUHUHMHFWHG7KHVHFRPSRXQGVD-KDQGZHUHTXLWH
ULJLGEHFDXVHRIWKHLQIOH[LELOLW\RIWKHVSLURF\FOLFVFDIIROGDQGWKHDPLGHOLQNHUJURXS
OHDYLQJRQO\RQHURWDWDEOHERQGEHWZHHQWKHKHWHURF\FOLFULQJDQGWKHDF\OJURXSUHVWULFWLQJ
WKXVWKHPRYHPHQWRIWKHEDVLFQLWURJHQRIWKHS\UUROLGLQHSLSHULGLQHULQJ,WZDVHQYLVDJHG
WKDWUHGXFWLRQRIWKHDPLGHJURXSWRSURGXFHWKHGLDPLQHVDQGZRXOGSURGXFHD
PRUHIOH[LEOHDUUDQJHPHQWDOORZLQJIRUDEHWWHULQWHUDFWLRQZLWKWKHFRQVHUYHGJOXWDPLFDFLG
UHVLGXHORFDWHGLQWKHVLWH,DOORVWHULFELQGLQJVLWH'LDPLQHVDEDQGZHUH
V\QWKHVLVHGDVGHVFULEHGHDUOLHUDQGDVVD\HGLQWKH[125I]-TARC SPA binding assay.  They 
were found to be between 0.9 and 1.4 log units more active than the respective amides 
making these analogues at least as active as 1.  The two enantiomers of 18a had identical 
affinity as the racemate, but had reduced solubility.  It was not possible to measure the pKa of 
the 1,2-diamino group spectrophotometrically, however, they were expected to be more basic 
than their D-amino amide analogues.  The Chemaxon calculated pKa for the proline nitrogen 
of 11a was 9.8, whereas it was 10.9 for 18a.  For comparison the calculated pKa for the 
homoproline nitrogen of 1 was 8.9, making these analogues very unlikely to have any 
permeability or oral absorption.  Compounds -18a, 23 and 27 were examined in the [35S]-
GTPJS functional assay, described in our earlier publications, and compared with 1, and the 
two site II antagonists 9 and 10.  In this assay all four site I antagonists were performing at 
the upper limit of the functional assay, and were found to be equipotent with a pIC50 of 8.1.  
Analogues -18a and 27 were progressed to the actin polymerisation in human PBMCs 
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assay, where -18a was found to be as active as 1, whereas 27 was less potent (pA2 = 6.0).  
By comparison the site II antagonists 9 and 10 had pA2 = 6.6 and 6.2 respectively, indicating 
that they were capable of crossing the cell lipid bilayer in this assay to reach their binding 
site.38  Following the very encouraging potency of -18a in the human blood assay, it was 
progressed to a pharmacokinetic study in vivo in the rat.  Compound -18a (dosed at 1 
mg/kg) was found to have negligible oral bioavailability, low clearance of 15 mL/min/kg 
(18% liver blood flow), moderate to high volume of distribution (5 L/kg) and a long half-life 
of 4 h.  In addition the human plasma protein binding was 93.2%. 
4. Receptor endocytosis studies 
CCL22 and CCL17 were shown to induce CCR4 receptor endocytosis (internalisation from 
the cell surface of human TH2 cells), resulting in a loss of functional responsiveness.45  
Internalisation of the receptor following agonist exposure is thought to be a means of receptor 
desensitisation in GPCRs.46  Endocytosis is an ATP-dependent process, which is largely 
inhibited at 4°C. Hence the antibody staining for the receptor endocytosis assays was 
performed at 4°C in all cases in order to confirm that there was receptor endocytosis and not 
simply inhibition of antibody binding by the test compounds.47  Our group has confirmed that 
binding to the orthosteric site with CCL22 or CCL17 induced concentration dependent 
reduction in cell surface expression of CCR4 receptors (pEC50 = 8.77 ± 0.08 and 7.98 ± 0.23 
respectively) on HUT78 cells.47  CCL22 induced almost complete receptor internalisation, 
whereas CCL17 caused only 50%.  The ability to induce endocytosis suggests that these 
CCR4 antagonists are in fact biased ligands with antagonist activity in the primary functional 
assays, but agonist activity in the receptor internalisation assay.47  However as receptor 
internalisation will prevent activation by chemokines this is really an antagonistic effect.  So 
we will continue to refer to these compounds as CCR4 antagonists.  Furthermore, four potent 
CCR4 antagonists (2, 4, 8 and 9) 
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the CCR4 receptor (compounds 2 and 4 bind to site I; compounds 8 and 9 to site II) were 
investigated for induction of receptor endocytosis.  The study showed that only the site I 
antagonists were capable of invoking internalisation (2: pEC50 = 8.0 ± 0.2 and 4: pEC50 = 6.4 
± 0.2).  The most potent antagonists from the spiro-pyrimidine series, compounds (R)-18a, 
(S)-18a, (±)-23 and (±)-27 were tested to assess their ability to invoke endocytosis of the 
CCR4 receptors on HUT78 cells (Table 2).  The antagonists were incubated with HUT78 
cells for 30 min at 37 oC and the CCR4 expression levels were evaluated by flow cytometry.  
The pEC50 is presented in Table 2 together with the degree of inhibition of receptor 
expression shown as a percentage.  As observed previously, the natural agonist CCL22 
inhibited cell surface expression almost completely.  The two enantiomers of 18a were found 
to be almost equipotent, with the R enantiomer showing a marginal advantage (R)-18a pEC50 
= 8.2 and (S)-18a pEC50 = 7.9.  The respective reduction in the number of cell surface CCR4 
was 64% and 56%.  The racemic difluoro analogue 23 also triggered internalisation of the 
receptor with a similar pEC50 and similar reduction in the number of receptors to that of the 
two enantiomers of 18a, however, the NMe analogue 27, which was the most potent spiro-
pyrimidine inhibitor in the SPA assay, had a lower pEC50 value in the HUT78 cells with over 
70% of cell surface CCR4 internalised.  We have shown previously that site II antagonists do 
possess activity in the F- actin polymerisation assay in isolated human PBMCs, and hence 
cross the cell membrane to reach their binding site.42  Therefore, the finding that site I 
compounds are capable of causing endocytosis, whereas site II are not, highlights an 
important aspect of CCR4 biology and not simply a difference in crossing the lipid bilayer of 
cell membranes.  Furthermore, it is important to note that this extremely interesting property 
of endocytosis is not a property commonly associated with small molecule antagonists.  Two 
reports of small molecule CCR3 and CXCR3 agonists emerged out of antagonists screens 
before publication of our findings with CCR4.48, 49  
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Figure 3.  Structure of Kirin CCR4 antagonist K777 
Recently the Kirin group reported that their CCR4 antagonist K777, the quaternary 
ammonium iodide 28 (Fig. 3) was capable of inducing CCR4 endocytosis at a concentration 
of 10 nM with a 50% reduction of cell surface CCR4.50  Furthermore, these authors suggested 
that 28 binds to one of the allosteric sites, but they were not able to define the exact binding 
site.  Considering the structure of 28 together with our earlier report that 2 and 4 bind to site I 
and cause CCR4 endocytosis,47 we speculate that 28 also binds to site I.  We have also 
considered CCR4 antagonists that were reported to possess in vivo activity, such as 5 
inhibiting ovalbumin-induced airway inflammation in guinea pigs,31 compounds 122 and 224 
in murine allergic inflammation models, and we note that all these compounds are site I 
CCR4 antagonists and that 2 and 18a cause receptor internalisation.  In contrast site II 
antagonists, such as 8 and 9 do not cause receptor internalisation, and none has been reported 
to possess any in vivo activity.  We therefore speculate whether the observed in vivo activity 
of site I CCR4 antagonists might be a consequence of their ability to induce endocytosis of 
the receptor.   
Having shown that site I CCR4 antagonists have activity in endocytosis assays the question 
arises whether these compounds should still be called antagonists?  We prefer to call them as 
biased signalling ligands as they have two properties, antagonism of orthosteric agonist drive 
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in F-actin, GTPȖS and chemotaxis assays, and agonism of receptor internalisation.  It is still 
correct to call them antagonists with respect to the functional effects. 
All of the site I antagonists are basic compounds with low permeabilities and unfavourable 
pharmacokinetic profiles.  Therefore, further investigations are required to identify CCR4 site 
I antagonists with improved pharmacokinetic properties.  The future directions and strategies 
for drug discovery in the field of small molecule antagonists and monoclonal antibodies 
targeting CCR4 have recently been reviewed by Pease.51  
5. Conclusion 
A number of 2,8-diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine derivatives were synthesized 
and screened as CCR4 antagonists.  Compound (±)-18a has high affinity in the [125I]-TARC 
binding assay with a pKi of 8.8, and the [35S]-GTPJS functional assay with a pIC50 of 8.1. 
Furthermore, it has high activity in the human whole blood actin polymerisation assay (pA2 = 
6.7).  The most potent antagonists were investigated for their ability to induce endocytosis of 
CCR4 and were found to partially internalise the receptor with pEC50 of about 8.  The two 
enantiomers of 18a were found to have identical binding affinities, and these were paralleled 
in the internalisation assay.  It is suggested that the in vivo activity of those allosteric CCR4 
antagonists binding to site I might be due to their ability to induce internalisation of the 
receptor. 
 
6. Experimental Section 
Organic solutions were dried over anhydrous Na2SO4 or MgSO4.  TLC was performed on 
Merck 0.25 mm Kieselgel 60 F254 plates.  Products were visualised under UV light and/or by 
staining with aqueous KMnO4 solution.  LCMS analysis was conducted on either System A 
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an Acquity UPLC BEH C18 column (2.1 mm × 50 mm i.d. 1.7 ȝPSDFNLQJGLDPHWHUeluting 
with 0.1% formic acid in water (solvent A), and 0.1 % formic acid in acetonitrile (solvent B), 
using the following elution gradient 0.0 ± 1.5 min 3 ± 100 % B, 1.5 ± 1.9 min 100% B, 1.9 ± 
2.0 min 3% B, at a flow rate of 1 mLmin±1 at 40 °C.  The UV detection was an averaged 
signal from wavelength of 210 nm to 350 nm, and mass spectra were recorded on a mass 
spectrometer using alternate-scan electrospray positive and negative mode ionization (ES+ve 
and ES-ve); or System B an Agilent Sunfire C18 column (30 mm u 4.6 mm ID, 3.5 µm 
packing diameter) eluting with 0.1% trifluoroacetic acid in water (solvent A), and 0.1% 
trifluoroacetic acid in MeCN (solvent B) using the following elution gradient 0.0 ± 4.2 min 3 
± 100% B, 4.2 ± 4.8 min 100% B, 4.8 ± 5.0 min 100 ± 3 % B at a flow rate of 3 mL min±1 at 
30 °C.  Column chromatography was performed on Flashmaster II, an automated multi-user 
flash chromatography system, utilizing disposable, normal phase, SPE cartridges (2 g to 100 
g).  Mass-directed auto-preparative HPLC (MDAP) for Method Awas conducted on a Sunfire 
C18 column (150 mm × 30 mm i.d. 5 ȝPSDFNLQJGLDPHWHUDWDPELHQWWHPSHUDWXUH eluting 
with 0.1 % TFA in water (solvent A) and 0.1 % TFA in acetonitrile (solvent B), using an 
appropriate elution gradient over 15 min at a flow rate of 40 mL min±1 and detecting at 210 ± 
350 nm at room temperature; for Method B was conducted on an Xbridge C18 column (150 
mm × 30 mm i.d. 5 ȝPSDFNLQJGLDPHWHUDWDPELHQWWHPSHUDWXUH eluting with 10 mM 
ammonium bicarbonate in water adjusted to pH 10 with ammonia (solvent A) and acetonitrile 
(solvent B), using an appropriate elution gradient over 15 min at a flow rate of 40 mL min±1 
and detecting at 210 ± 350 nm at room temperature.  Mass spectra were recorded on 
Micromass ZMD mass spectrometer using electro spray positive and negative mode, alternate 
scans.  The software used was MassLynx 3.5 with OpenLynx and FractionLynx options.  1H 
NMR spectra were recorded at 400 MHz, unless otherwise stated.  The chemical shifts are 
expressed in ppm relative to tetramethylsilane.  High resolution positive ion mass spectra 
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were acquired on a Micromass Q-Tof 2 hybrid quadrupole time-of-flight mass spectrometer.  
Optical rotations were measured with an Optical Activity AA100 digital polarimeter.  
Analytical chiral HPLC was conducted on Chiralpak column (250 mm u 4.6 mm) eluting 
with an appropriate ratio of EtOH-heptane for 30 min at room temperature, flow rate 1 mL 
min±1 injection volume 15 PL detecting at 215 nm.  The purity of all compounds screened in 
the biological assays was examined by LCMS analysis and was found to be t 95%, unless 
otherwise specified.  All animal studies were ethically reviewed and carried out in accordance 
with Animals (Scientific Procedures) Act 1986 and the GSK Policy on the Care, Welfare and 
Treatment of Laboratory Animals.  The human biological samples were sourced ethically and 
their research use was in accord with the terms of the informed consents. 
6.1 (R)-(8-(4-((2,4-Dichlorobenzyl)amino)pyrimidin-2-yl)-2,8-diazaspiro[4.5]decan-2-
yl)(pyrrolidin-2-yl)methanone (R)-(11a) 
A mixture of 17 (100 mg, 0.22 mmol), (R)-N-BOC-proline (52 mg, 0.24 mmol), HATU (54.3 
mg, 0.14 mmol) and DIPEA (0.122 mL, 0.7 mmol) in DMF (1 mL) was stirred at ambient 
temperature for 1 h. The reaction mixture was purified by MDAP (Method A) the appropriate 
fractions were evaporated under reduced pressure. The residue was dissolved in DCM (0.5 
mL) and TFA (0.5 mL) and stirred for 0.5 h. The solvent was evaporated under reduced 
pressure and the residue was dissolved in MeOH (0.5 mL) and passed down an aminopropyl 
cartridge (0.5 g). The cartridge was eluted with MeOH and the filtrate was evaporated under 
reduced pressure to give (R)-11a (85 mg, 79%) as a colourless gum: >Į@D20 = +36 (c = 0.93 in 
MeOH); 1H NMR G (400 MHz, CD3OD) 7.70 (d, J = 6.0 Hz, 1H), 7.43 (d, J = 2.0 Hz, 1H), 
7.33 (d, J = 8.0 Hz, 1H), 7.26 (dd, J = 8.0, 2.0 Hz, 1H), 5.85 (d, J = 6.0 Hz, 1H), 4.58 (s, 2H), 
3.85 ± 3.41 (m, 9H), 3.20 ± 3.05 (m, 1H), 2.85 ± 2.69 (m, 1H), 2.28 ± 2.04 (m, 1H), 1.90 (t, J 
= 7.0 Hz, 1H), 1.86 ± 1.70 (m, 3H), 1.72 ± 1.58 (m, 1H), 1.51 ± 1.41 (m, 4H); the two 
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exchangeable protons were not observed; 13C NMR G (126 MHz, CD3OD) 174.4, 174.3, 
164.3, 162.7, 155.7, 137.7, 135.0, 134.9, 134.2, 131.2, 130.1, 128.3, 96.8, 60.3, 60.0, 57.2, 
56.9, 48.3, 45.9, 45.8, 43.0, 42.8, 42.7, 42.6, 40.8, 37.1, 35.3, 35.2, 35.1, 35.0, 31.4, 31.3, 
27.4 (the additional peaks were observed due to rotamers); 13C NMR G (101 MHz, DMSO-d6, 
393.2 K) 171.7, 161.9, 160.8, 154.7, 135.9, 132.5, 131.4, 129.8, 127.8, 126.4, 94.3, 58.4, 
54.9, 47.9, 46.4, 43.2 (2C), 33.3 (2C), 28.9, 25.4; IR ȣmax (neat) 3302, 2925, 2868, 1634, 
1588, 1492, 1450 cm-1; Anal. Calcd. for C24H31Cl2N6O = 489.1931. Found = 489.1925 
[M+H]+; LCMS (System A, UV, ES) RT = 0.67 min, [M+H]+ = 489, 491, 493 100% purity. 
6.2 (S)-(8-(4-((2,4-Dichlorobenzyl)amino)pyrimidin-2-yl)-2,8-diazaspiro[4.5]decan-2-
yl)(pyrrolidin-2-yl)methanone (S)-(11a) 
Was prepared by a similar method to its enantiomer to give (21 mg, 56%) as a colourless 
gum: >Į@D20 = ±37 (c = 1.08 in MeOH); LCMS (System A, UV, ES) RT = 0.67 min, [M+H]+ 
= 489, 491, 493 100% purity. Other spectroscopic data were identical to its enantiomer. 
6.3 (R)-(8-(4-((2,4-Dichlorobenzyl)amino)pyrimidin-2-yl)-2,8-diazaspiro[4.5]decan-2-
yl)(piperidin-2-yl)methanone (R)-(11b) 
Was prepared from 17 (30 mg, 0.076 mmol) and (R)-1-(tert-butoxycarbonyl)piperidine-2-
carboxylic acid (19 mg, 0.084 mmol) according to the procedure described for the 
preparation of (R)-11a to give (R)-11b (15 mg, 39%) as a colourless gum: >Į@D20 = +12 (c = 
1.03 in MeOH); 1H NMR G (400 MHz, CD3OD) 7.71 (d, J = 6.0 Hz, 1H), 7.43 (t, J = 2.0 Hz, 
1H), 7.34 (d, J = 8.0 Hz, 1H), 7.26 (dd, J = 8.0, 2.0 Hz, 1H), 5.86 (d, J = 6.0 Hz, 1H), 4.58 (s, 
2H), 3.87 ± 3.62 (m, 4H), 3.61 ± 3.42 (m, 4H), 3.29 ± 3.19 (m, 1H), 3.14 ± 3.02 (m, 1H), 2.72 
± 2.55 (m, 1H), 1.89 (t, J = 7.0 Hz, 2H), 1.80 (t, J = 7.0 Hz, 2H), 1.68 ± 1.54 (m, 2H), 1.52 ± 
1.31 (m, 6H); the two exchangeable protons were not observed; 13C NMR G (126 MHz, 
CD3OD) 174.0, 173.9, 164.2, 162.7, 162.6, 155.7, 137.7, 134.9, 134.8, 134.2, 131.2, 130.1, 
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128.3, 96.8, 58.9, 58.7, 57.3, 56.5, 46.3, 46.2, 45.9, 45.5, 42.9, 42.8, 42.7, 42.6, 40.8, 37.1, 
35.3, 35.2, 35.1, 35.0, 30.4, 30.3, 27.2, 25.2, 25.1 (the additional peaks were observed due to 
rotamers); Anal. Calcd. for C25H33Cl2N6O = 503.2087. Found = 503.2075 [M+H]+; LCMS 
(System A, UV, ES) RT = 0.68 min, [M+H]+ = 503, 505, 507, 100% purity. 
6.4 (S)-(8-(4-((2,4-Dichlorobenzyl)amino)pyrimidin-2-yl)-2,8-diazaspiro[4.5]decan-2-
yl)(piperidin-2-yl)methanone (S)-(11b) 
Was prepared from 17 (30 mg, 0.076 mmol) and (S)-1-(tert-butoxycarbonyl)piperidine-2-
carboxylic acid (19 mg, 0.084 mmol) according to the procedure described for the 
preparation of (R)-11a to give (S)-11b (14 mg, 36%) as a colourless gum: >Į@D20 = ±11 (c = 
1.04 in MeOH); LCMS (System A, UV, ES) RT = 0.68 min, [M+H]+ = 503, 505, 507, 100% 
purity. Other spectroscopic data identical to its enantiomer. 
6.5 (±)-(8-(4-((2,4-Dichlorobenzyl)amino)pyrimidin-2-yl)-2,8-diazaspiro[4.5]decan-2-
yl)(pyrrolidin-3-yl)methanone (11c) 
Was prepared from 17 (30 mg, 0.076 mmol) and (±)-N-BOC-pyrrolidine-3-carboxylic acid 
(18 mg, 0.084 mmol) according to the same procedure described for the preparation of (R)-
11a to give (±)-11c (12 mg, 32%) as a colourless gum: 1H NMR G (400 MHz, CD3OD) 7.70 
(d, J = 6.0 Hz, 1H), 7.43 (br.s, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.25 (dd, J = 8.0, 2.0 Hz, 1H), 
5.85 (d, J = 6.0 Hz, 1H), 4.58 (s, 2H), 3.84 ± 3.61 (m, 4H), 3.60 ± 3.38 (m, 4H), 3.18 ± 3.08 
(m, 1H), 3.08 ± 2.95 (m, 3H), 2.90 ± 2.79 (m, 1H), 2.14 ± 2.00 (m, 1H), 1.95 ± 1.85 (m, 2H), 
1.84 ± 1.77 (m, 1H), 1.54 ± 1.41 (m, 4H); the two exchangeable protons were not observed; 
13C NMR G (126 MHz, CD3OD) 176.2, 176.0, 164.3, 162.7, 155.7, 137.7, 134.9, 134.2, 
131.2, 130.1, 128.3, 96.8, 57.9, 56.7, 51.5, 51.4, 48.3, 48.2, 46.4, 45.6, 44.1, 43.8, 42.9, 42.8, 
42.7, 42.6, 40.9, 37.1, 35.3, 35.3, 35.1, 35.0, 31.6 (the additional peaks were observed due to 
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rotamers); Anal. Calcd. for C24H31Cl2N6O = 489.1931. Found = 489.1917 [M+H]+; LCMS 
(System A, UV, ES) RT = 0.67 min, [M+H]+ = 489, 491, 493, 100% purity. 
6.6 (±)-(8-(4-((2,4-Dichlorobenzyl)amino)pyrimidin-2-yl)-2,8-diazaspiro[4.5]decan-2-
yl)(piperidin-3-yl)methanone (11d) 
Was prepared from 17 (30 mg, 0.076 mmol) and (±)-1-(tert-butoxycarbonyl)piperidine-3-
carboxylic acid (19 mg, 0.084 mmol) according to the procedure described for the 
preparation of (R)-17a to give (±)-11d (23 mg, 60%) as a colourless gum: 1H NMR G (500 
MHz, CD3OD) 7.70 (dd, J = 6.0, 2.5 Hz, 1H), 7.43 (s, 1H), 7.37 ± 7.31 (m, 1H), 7.26 (d, J 
=8.0 Hz, 1H), 5.85 (br. s, 1H), 4.58 (s, 2H), 3.82 ± 3.61 (m, 4H), 3.59 ± 3.50 (m, 1H), 3.50 ± 
3.38 (m, 2H), 3.06 ± 2.87 (m, 2H), 2.80 ± 2.50 (m, 3H), 1.94 ± 1.84 (m, 2H), 1.80 (t, J = 7.0 
Hz, 1H), 1.75 ± 1.59 (m, 2H), 1.58 ± 1.24 (m, 5H), 1.01 ± 0.81 (m, 1H); the two 
exchangeable protons were not observed; 13C NMR G (126 MHz, CD3OD) 175.5, 175.4, 
162.7, 134.9, 134.8, 134.2, 132.6, 131.2, 130.1, 130.0, 128.3, 69.3, 57.7, 56.6, 46.9, 46.1, 
45.4, 42.9, 42.8, 42.7, 42.6, 40.9, 40.3, 37.1, 35.3, 35.2, 35.1, 31.8, 30.3, 28.3, 26.2, 25.1, 
24.2, 14.6, 11.6 (the additional peaks were observed due to rotamers); Anal. Calcd. for 
C25H33[35Cl]2N6O = 503.2087. Found = 503.2078 [M+H]+; LCMS (System A, UV, ES) RT = 
0.65 min, [M+H]+ =503, 505, 507, 98% purity. 
6.7 1-(8-(4-((2,4-Dichlorobenzyl)amino)pyrimidin-2-yl)-2,8-diazaspiro[4.5]decan-2-
yl)-2-(methylamino)ethanone (11e) 
Was prepared from 17 (30 mg, 0.076 mmol) and N-BOC-sarcosine (15 mg, 0.084 mmol) 
according to the procedure described for the preparation of (R)-11a to give 11e (23 mg, 44%) 
as the bis-TFA salt; 1H NMR G (400 MHz, CD3OD) 7.62 (dd, J = 7.0, 2.0 Hz, 1H), 7.50 (d, J 
= 2.0 Hz, 1H), 7.41 ± 7.36 (m, 1H), 7.35 ± 7.29 (m, 1H), 6.20 (dd, J = 7.0, 2.0 Hz, 1H), 4.72 
(s, 2H), 3.98 (s, 2H), 3.87 ± 3.63 (m, 5H), 3.63 ± 3.50 (m, 2H), 3.46 ± 3.35 (m, 1H), 2.75 (s, 
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3H), 1.99 (t, J = 7.0 Hz, 1H), 1.90 (t, J = 7.0 Hz, 1H), 1.66 (br. s, 4H); the four exchangeable 
protons were not observed; Anal. Calcd. for C22H29[35Cl]2N6O = 463.1774. Found = 463.1776 
[M+H]+; LCMS (System A, UV, ES) RT = 0.60 min, [M+H]+ = 463, 465, 99% purity. The 
free base was formed by dissolving the salt in methanol (0.5 mL) and by passing through an 
aminopropyl cartridge (0.5 g). The cartridge was washed with additional methanol, and the 
filtrate was concentrated to afford 11e (15 mg, 42%) as a white solid: 1H NMR G (400 MHz, 
DMSO-d6) 7.74 (d, J = 4.5 Hz, 1H), 7.59 (d, J = 2.0 Hz, 2H), 7.40 (dd, J = 8.0, 2.0 Hz, 1H), 
7.35 (d, J = 8.0 Hz, 1H), 5.82 (br. s, 1H), 4.50 (d, J = 5.0 Hz, 2H), 3.78 ± 3.63 (m, 2H), 3.59 
± 3.47 (m, 4H), 3.45 (t, J = 7.5 Hz, 2H), 3.20 (br. s, 2H), 2.27 (d, J = 2.5 Hz, 3H), 1.77 (t, J = 
7.0 Hz, 1H), 1.67 (t, J = 7.0 Hz, 1H), 1.44 ± 1.23 (m, 4H); Anal. Calcd. for C22H29[35Cl]2N6O 
= 463.1774. Found = 463.1776 [M+H]+; LCMS (System A, UV, ES) RT = 0.61 min, [M+H]+ 
= 463, 465, 467, 100% purity. 
6.8 Cyclohexyl(8-(4-((2,4-dichlorobenzyl)amino)pyrimidin-2-yl)-2,8-
diazaspiro[4.5]decan-2-yl)methanone (11f) 
Was prepared from 17 (30 mg, 0.076 mmol) and cyclohexanecarboxylic acid (12 mg, 0.084 
mmol) according to the procedure described for the preparation of 11a to give 11f (20 mg, 
52%) as a colourless gum: 1H NMR G (400 MHz, CD3OD) 7.73 (dd, J = 6.0, 2.0 Hz, 1H), 
7.46 (t, J = 2.0 Hz, 1H), 7.37 (d, J = 8.0 Hz, 1H), 7.29 (dd, J = 8.0, 2.0 Hz, 1H), 5.88 (d, J = 
6.0 Hz, 1H), 4.61 (s, 2H), 3.84 ± 3.63 (m, 4H), 3.62 ± 3.53 (m, 1H), 3.50 (t, J = 7.0 Hz, 1H), 
3.42 (s, 1H), 2.62 ± 2.43 (m, 1H), 1.91 (t, J = 7.0 Hz, 1H), 1.87 ± 1.67 (m, 6H), 1.59 ± 1.12 
(m, 10H); the exchangeable proton was not observed; 13C NMR G (126 MHz, CD3OD) 177.6, 
177.5, 164.2, 162.5, 162.48 155.5, 137.6, 134.8, 134.78, 134.1, 131.1, 130.0, 128.2, 96.8, 
57.7, 56.5, 45.9, 45.3, 43.8, 43.7, 42.7, 42.7, 42.6, 42.5, 40.7, 37.0, 35.2, 35.0, 34.9, 30.1, 
30.0, 27.0, 26.8, 26.7 (the additional peaks were observed due to rotamers); Anal. Calcd. for 
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C26H34[35Cl]2N5O = 502.2135. Found = 502.2118 [M+H]+; LCMS (System A, UV, ES) RT = 
1.01 min, [M+H]+ = 502, 504, 506, 100% purity. 
6.9 (8-(4-((2,4-Dichlorobenzyl)amino)pyrimidin-2-yl)-2,8-diazaspiro[4.5]decan-2-
yl)(pyridin-2-yl)methanone (11g) 
Was prepared from 17 (30 mg, 0.076 mmol) and pyridine-2-carboxylic acid (10 mg, 0.084 
mmol) according to the procedure described for the preparation of 11a to give 11g (18 mg, 
47%) as a colourless gum: 1H NMR (500 MHz, CD3OD) 8.62 (d, J = 4.5 Hz, 1H), 8.04 ± 7.92 
(m, 1H), 7.81 ± 7.65 (m, 2H), 7.55 ± 7.49 (m, 1H), 7.46 (dd, J = 8.5, 2.0 Hz, 1H), 7.39 ± 7.32 
(m, 1H), 7.31 ± 7.23 (m, 1H), 5.91 ± 5.80 (m, 1H), 4.60 (d, J = 15.0 Hz, 2H), 3.84 ± 3.77 (m, 
1H), 3.74 (t, J = 7.0 Hz, 2H), 3.70 ± 3.50 (m, 5H), 1.95 ± 1.83 (m, 2H), 1.64 ± 1.39 (m, 4H), 
the exchangeable NH proton was not observed; 1H NMR G (400 MHz, DMSO-d6, 393 K) 8.59 
(d, J = 5.0 Hz, 1H), 7.89 (dt, J = 8.0, 1.5 Hz, 1H), 7.77 (d, J = 6.0 Hz, 1H), 7.70 (d, J = 8.0 
Hz, 1H), 7.48 (d, J = 2.0 Hz, 1H), 7.46 ± 7.39 (m, 2H), 7.37 ± 7.28 (m, 1H), 7.01 (br. s, 1H), 
5.84 (d, J = 6.0 Hz, 1H), 4.55 (br. s, 2H), 3.75 ± 3.57 (m, 6H), 3.50 (s, 2H), 1.82 (t, J = 7.0 
Hz, 2H), 1.49 (br. s, 4H); 13C NMR G (126 MHz, CD3OD) 169.0, 168.9, 162.7, 162.6, 155.3, 
149.7, 149.6, 139.0, 139.0, 134.9, 134.2, 131.2, 130.1, 130.1, 128.3, 128.3, 126.7, 126.6, 
124.7, 124.7, 60.0, 57.5, 46.3, 43.2, 42.8, 42.6, 40.9, 37.6, 35.4, 34.9 (the additional peaks 
were observed due to rotamers); Anal. Calcd. for C25H27[35Cl]2N6O = 497.1618. Found = 
497.1610 [M+H]+; LCMS (System A, UV, ES) RT = 0.86 min, [M+H]+ = 497, 499, 501, 
98% purity. 
6.10 (±)-(8-(4-((2,4-Dichlorobenzyl)amino)pyrimidin-2-yl)-2,8-diazaspiro[4.5]decan-2-
yl)(morpholin-3-yl)methanone (11h) 
Was prepared from 17 (30 mg, 0.076 mmol) and (±)-4-(tert-butoxycarbonyl)morpholine-3-
carboxylic acid (19 mg, 0.084 mmol) according to the procedure described for the 
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preparation of 11a to give 11h (20 mg, 52%) as a colourless oil: 1H NMR G (400 MHz, 
CD3OD) 7.70 (d, J = 6.0 Hz, 1H), 7.44 (br. s, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.26 (dd, J = 8.0, 
1.5 Hz, 1H), 5.86 (d, J = 6.0 Hz, 1H), 4.58 (br. s, 2H), 4.02 ± 3.88 (m, 1H), 3.84 ± 3.42 (m, 
9H), 3.40 ± 3.24 (m, 3H, (obscured by CD3OD), 2.96 ± 2.88 (m, 2H), 1.89 (t, J = 7.0 Hz, 1H), 
1.80 (t, J = 7.0 Hz, 1H), 1.56 ± 1.29 (m, 4H); the two exchangeable protons were not 
observed; 13C NMR G (126 MHz, CD3OD) 170.8, 170.7, 164.2, 162.7, 155.7, 137.7, 134.9, 
134.9, 134.2, 131.2, 130.1, 128.3, 96.8, 69.8, 68.5, 57.9, 57.8, 57.4, 56.6, 46.0, 45.6, 45.4, 
45.3, 43.0, 42.8, 42.7, 42.6, 40.8, 37.1, 35.3, 35.2, 35.1, 34.9 (the additional peaks were 
observed due to rotamers); Anal. Calcd. for C24H31[35Cl]2N6O2 = 505.1880. Found = 
505.1878 [M+H]+; LCMS (System A, UV, ES) RT = 0.62 min, [M+H]+ = 505, 507, 509, 
100% purity. 
6.11 4-Chloro-N-(2,4-dichlorobenzyl)pyrimidin-2-amine (13) and 2-chloro-N-(2,4-
dichlorobenzyl)pyrimidin-4-amine (14) 
2,4-Dichlorobenzylamine (1.0 mL, 7.4 mmol) was added to a stirring solution of 2,4-
dichloropyrimidine (1.0 g, 6.7 mmol) and DIPEA (1.8 mL, 10.1 mmol) in anhydrous DCE 
(10 mL) and the reaction mixture was stirred at 20°C under a nitrogen atmosphere for 24 h. 
LCMS showed the presence of a mixture of regioisomers (System A, RT = 1.10 min, 63% 
and 1.25 min, 27%). The reaction mixture was diluted with water (50 mL) and extracted with 
DCM (3 × 50 mL). The combined organic extracts were washed with brine (50 mL), dried 
using a hydrophobic frit and evaporated under reduced pressure. The residue was purified by 
column chromatography on a silica column, using a gradient of 0-100% ethyl acetate-
cyclohexane over 40 min. The appropriate fractions were combined and evaporated under 
reduced pressure to afford the two regioisomers as white solids: less-polar isomer 13 (400 
mg, 21%): 1H NMR G (400 MHz, DMSO-d6) 8.33 ± 8.11 (m, 2H), 7.60 (d, J = 2.0 Hz, 1H), 
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7.43 ± 7.28 (m, 2H), 6.74 (d, J = 5.0 Hz, 1H), 4.51 (d, J = 5.0 Hz, 2H); 13C NMR G (126 
MHz, DMSO-d6) 162.1, 160.1, 159.9, 135.6, 132.9, 132.1, 129.6, 128.6, 127.3, 109.8, 41.7; 
IR ȣmax (neat) 3269, 1597, 1561, 1531, 1449, 1412  cm-1; Anal. Calcd. for C11H9[35Cl]3N3 = 
287.9857. Found = 287.9860, [M+H]+; LCMS (System A, UV, ES) RT = 1.25 min, [M+H]+ 
= 288, 290, 292, 294 100% purity; and the more-polar isomer 14 (950 mg, 49%): 1H NMR G 
(400 MHz, DMSO-d6) 8.42 (t, J = 4.5 Hz, 1H), 7.97 (d, J = 5.0 Hz, 1H), 7.63 (d, J = 2.0 Hz, 
1H), 7.45 ± 7.29 (m, 2H), 6.58 (d, J = 5.0 Hz, 1H), 4.54 (d, J = 4.5 Hz, 2H); 13C NMR G (101 
MHz, DMSO-d6) 163.4, 159.7, 155.8, 134.8, 133.3, 132.5, 130.6, 128.7, 127.4, 105.2, 41.0; 
IR ȣmax (neat) 3263, 1591, 1563, 1467, 1337 cm-1; Anal. Calcd. for C11H9[35Cl]3N3 = 
287.9857. Found = 287.9860, [M+H]+; LCMS (System A, UV, ES) RT = 1.10 min, [M+H]+ 
= 288, 290, 292, 100% purity. 
6.12 tert-Butyl 8-(4-((2,4-dichlorobenzyl)amino)pyrimidin-2-yl)-2,8-
diazaspiro[4.5]decane-2-carboxylate, hydrochloride salt (16) 
tert-Butyl 2,8-diazaspiro[4.5]decane-2-carboxylate (15) (1.67 g, 6.93 mmol) was added to a 
stirring solution of 14 (2.00 g, 6.93 mmol) in i-PrOH (9 mL) and the mixture was heated to 
90 °C for 48 h.  The reaction mixture was allowed to cool to 20 °C and diethyl ether (10 mL) 
was added.  The resulting solid was collected by filtration, washed with more diethyl ether 
and dried overnight to give 16 (3.3 g, 90%) as a white solid: 1H NMR G (400 MHz, CD3OD) 
7.61 (d, J = 7.0 Hz, 1H), 7.51 (d, J = 2.0 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.33 (dd, J = 8.0, 
2.0 Hz, 1H), 6.20 (d, J = 7.0 Hz, 1H), 4.72 (s, 2H), 3.87 ± 3.61 (m, 4H), 3.47 ± 3.37 (m, 2H), 
3.24 (s, 2H), 1.85 (t, J = 7.0 Hz, 2H), 1.66 ± 1.58 (m, 4H), 1.47 (s, 9H); the two exchangeable 
protons were not observed; 13C NMR G (126 MHz, MeOD-d4) 164.0, 156.7, 153.8, 142.1, 
135.5, 135.4, 135.3, 132.1, 130.5, 128.7, 99.2, 81.2, 81.1, 57.2, 56.3, 45.6, 45.3, 43.8, 43.7, 
43.4, 42.0, 41.2, 36.7, 35.6, 34.9, 28.9 (the additional peaks were observed due to rotamers); 
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IR ȣmax (neat) 3230, 2922, 2962, 1687, 1655, 1619, 1581, 1406 cm-1; Anal. Calcd. for 
C24H32[35Cl]2N5O2 = 492.1928. Found = 492.1918, [M+H]+; LCMS (System A, UV, ES) RT 
= 1.04 min, [M+H]+ = 492, 494, 496, 100% purity. 
6.13 N-(2,4-Dichlorobenzyl)-2-(2,8-diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine (17) 
Compound 16 (455 mg, 0.860 mmol) was treated with 4M HCl in dioxane (3.0 mL) and the 
mixture was stirred at ambient temperature for 0.5 h.  The reaction mixture was concentrated 
under reduced pressure and the residue was dissolved in DCM (20 mL), re-evaporated under 
reduced pressure, and dried in vacuo to give 17.2HCl as a white solid (400 mg, 99%): 1H 
NMR G (400 MHz, CD3OD) 7.67 (d, J = 7.0 Hz, 1H), 7.50 (d, J = 2.0 Hz, 1H), 7.44 (d, J = 
8.0 Hz, 1H), 7.35 (dd, J = 8.0, 2.0 Hz, 1H), 6.28 (d, J = 7.0 Hz, 1H), 4.74 (s, 2H), 3.92 ± 3.81 
(m, 2H), 3.80 ± 3.71 (m, 2H), 3.47 (t, J = 7.5 Hz, 2H), 3.24 (s, 2H), 2.06 (t, J = 7.5 Hz, 2H), 
1.86 ± 1.66 (m, 4H); the four exchangeable protons were not observed; 13C NMR G (126 
MHz, CD3ODį164.0, 153.7, 142.1, 135.3, 135.2, 132.1, 130.4, 128.7, 99.3, 55.3, 45.6, 
43.7, 43.3, 42.6, 35.6, 34.9; IR ȣmax (neat) 3431, 3355, 2869, 2827, 1650, 1617, 1574, 1467, 
1410 cm-1; Anal. Calcd. for C19H24[35Cl]2N5 = 392.1403. Found = 392.1408, [M+H]+; LCMS 
(System A, UV, ES) RT = 0.56 min, [M+H]+ = 392, 394, 396, 100% purity.   The free base 
was obtained by passing down an aminopropyl cartridge (40 g) eluting with MeOH and 
concentrating under reduced pressure: 1H NMR G (400 MHz, CD3OD) 7.71 (d, J = 6.0 Hz, 
1H), 7.44 (d, J = 2.0 Hz, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.26 (dd, J = 8.0, 2.0 Hz, 1H), 5.87 (d, 
J = 6.0 Hz, 1H), 4.59 (s, 2H), 3.78 ± 3.65 (m, 2H), 3.64 ± 3.54 (m, 2H), 3.35 (s, 2H), 3.19 (t, 
J = 7.5 Hz, 2H), 2.93 (s, 2H), 1.82 (t, J = 7.5 Hz, 2H), 1.49 (t, J = 5.5 Hz, 4H); the two 
exchangeable protons were not observed;  Anal. Calcd. for C19H24[35Cl]2N5 = 392.1403. 
Found = 392.1408, [M+H]+; LCMS (System A, UV, ES) RT = 0.55 min, [M+H]+ = 392, 394, 
396, 95% purity. 
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6.14 (R)-N-(2,4-Dichlorobenzyl)-2-(2-(pyrrolidin-2-ylmethyl)-2,8-
diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine (R)-(18a) 
LiAlH4 (0.20 mL of a 1 M solution in diethyl ether, 0.20 mmol) was added to a solution of 
(R)-11a (75 mg, 0.14 mmol) in THF (1 mL) at 0 ºC, and the reaction mixture was stirred at 
URRPWHPSHUDWXUHIRUK:DWHUȝ/ZDVDGGHGIROORZHGE\DTXeous sodium hydroxide 
ȝ/RI0VROXWLRQDQGPRUHZDWHUȝ/7KHUHDFWLRQZDVVWLUUHGDWURRPWHPSHUDWXUH
for 0.5 h, anhydrous MgSO4 was then added and the mixture was stirred for an additional 15 
min, before being filtered under vacuum. The filtrate was then partitioned between EtOAc 
(10 mL) and water (10 mL). The organic layer was separated, and the aqueous layer was 
extracted with more EtOAc (3 × 10 mL). The combined organic layers were dried using a 
hydrophobic frit and concentrated under reduced pressure. The crude product was taken up in 
DMSO (1 mL) and purified by MDAP (Method A). The solvent was evaporated and the solid 
was taken up in MeOH (1 mL) and passed through an aminopropyl cartridge (1 g). The 
cartridge was washed with additional methanol and the eluant was evaporated under reduced 
pressure to give (R)-18a (34 mg, 50%) as a colourless gum: >Į@D20 = ±5.1 (c = 0.47 in 
MeOH); Chiral HPLC RT = 36.5 min, 99.4% chiral purity (Chiralpak AD, 250 × 4.6 mm, 5% 
EtOH-heptane (containing 0.1% isopropylamine), flow rate of 1 mL/min); 1H NMR (500 
MHz, CD3OD) 7.68 (d, J = 6.0 Hz, 1H), 7.42 (d, J = 1.5 Hz, 1H), 7.33 (d, J = 8.0 Hz, 1H), 
7.24 (dd, J = 8.0, 1.5 Hz, 1H), 5.83 (d, J = 6.0 Hz, 1H), 4.57 (s, 2H), 3.79 ± 3.43 (m, 4H), 
3.19 ± 3.07 (m, 1H), 3.00 ± 2.89 (m, 1H), 2.83 ± 2.75 (m, 1H), 2.71 ± 2.64 (m, 1H), 2.63 ± 
2.56 (m, 1H), 2.56 ± 2.33 (m, 4H), 1.97 ± 1.87 (m, 1H), 1.81 ± 1.71 (m, 2H), 1.66 (t, J = 7.0 
Hz, 2H), 1.56 ± 1.21 (m, 5H); the two exchangeable NH protons were not observed; 13C 
NMR G (126 MHz, CD3OD) 164.2, 162.7, 155.7, 137.7, 134.9, 134.2, 131.2, 130.1, 128.3, 
96.5, 67.5, 62.8, 58.4, 55.2, 46.8, 43.1, 43.0, 41.8, 38.8, 37.8, 31.4, 25.9; IR ȣmax (neat) 3300, 
2922, 1587, 1491, 1448, 1338 cm-1; Anal. Calcd. for C24H33[35Cl]2N6 = 475.2138. Found = 
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457.2134; [M+H]+; LCMS (System A, UV, ES) RT = 0.57 min, [M+H]+ = 475, 477, 479, 
97% purity.  
6.15 (S)-N-(2,4-Dichlorobenzyl)-2-(2-(pyrrolidin-2-ylmethyl)-2,8-
diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine (S)-(18a)  
>Į@D20 = +8.5 (c = 0.50 in MeOH); Chiral HPLC RT = 41.7 min, 97% chiral purity (Chiralpak 
AD, 250 × 4.6 mm, 5% ethanol-heptane [0.1% isopropylamine], flow rate of 1 mL/min); 
other spectroscopic data were identical to its enantiomer (R)-18a. 
6.16 N-(2,4-Dichlorobenzyl)-2-(2-(pyrrolidin-2-ylmethyl)-2,8-diazaspiro[4.5]decan-8-
yl)pyrimidin-4-amine -D 
5-WHUW-%XW\O-IRUP\OS\UUROLGLQH--FDUER[\ODWHP/PPROZDVDGGHGWRD
PL[WXUHRIPJPPRODQG$PROHFXODUVLHYHVPJLQ'&0P/DQG
WKHUHDFWLRQZDVVWLUUHGDWDPELHQWWHPSHUDWXUHXQGHUDQLWURJHQDWPRVSKHUHIRUPLQ
$FHWLFDFLG/PPRODQGVRGLXPWULDFHWR[\ERURK\GULGHPJPPRO
ZHUHDGGHGDQGWKHUHDFWLRQPL[WXUHZDVVWLUUHGIRUDQDGGLWLRQDOK7KHPL[WXUHZDV
SDUWLWLRQHGEHWZHHQ'&0P/DQGZDWHUP/WKHRUJDQLFOD\HUZDVVHSDUDWHG
ZDVKHGZLWKZDWHUîP/GULHGXVLQJDK\GURSKRELFIULWDQGFRQFHQWUDWHGXQGHU
UHGXFHGSUHVVXUH7)$P/ZDVWKHQDGGHGWRWKHUHVLGXHDQGWKHPL[WXUHZDVVWLUUHGDW
DPELHQWWHPSHUDWXUHIRUK7KHUHDFWLRQPL[WXUHZDVFRQFHQWUDWHGXQGHUUHGXFHGSUHVVXUH
DQGWKHUHVLGXHZDVGLVVROYHGLQ'062P/DQGSXULILHGE\0'$30HWKRG$7KH
VROYHQWZDVHYDSRUDWHGDQGWKHVROLGZDVWDNHQXSLQ0H2+P/SDVVHGWKURXJKDQ
DPLQRSURS\OFDUWULGJHJZDVKHGZLWK0H2+DQGWKHILOWUDWHZDVHYDSRUDWHGXQGHU
UHGXFHGSUHVVXUHWRDIIRUG-DPJDVDZKLWHVROLG/&060HWKRG$89
(657 PLQ>0+@ SXULW\$QDO\WLFDOFKLUDO+3/&57 
PLQDQGPLQRQD&KLUDOSDN$'FROXPQîPPHOXWLQJZLWK(W2+±
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KHSWDQHFRQWDLQLQJLVRSURS\ODPLQHIORZ-UDWHP/PLQLQGLFDWLQJUDFHPLVDWLRQ
RFFXUHGGXULQJWKHUHGXFWLYHDPLQDWLRQ$SRUWLRQRI-DPJZDVUHVROYHGE\
SUHSDUDWLYHFKLUDO+3/&RQD&KLUDOSDN$'-+PPuPPFROXPQHOXWLQJ
LVRFUDWLFDOO\ZLWK(W2+±KH[DQHFRQWDLQLQJLVRSURS\ODPLQHRYHUPLQIORZ-
UDWHP/PLQFROOHFWLQJIUDFWLRQVZLWK57 -PLQDQG-PLQUHVSHFWLYHO\7KH
DSSURSULDWHIUDFWLRQVZHUHFRQFHQWUDWHGWRJLYHWKHWZRHQDQWLRPHUVPJIRUHDFK
HQDQWLRPHU 
6.17 (±)-N-(2,4-Dichlorobenzyl)-2-(2-(piperidin-2-ylmethyl)-2,8-diazaspiro[4.5]decan-
8-yl)pyrimidin-4-amine (18b) 
Borane.THF complex (0.08 mL of a 1 M solution in THF, 0.08 mmol) was added to a stirring 
solution of 11b (16 mg, 0.016 mmol) in THF (0.2 mL) and the reaction mixture was stirred at 
ambient temperature for 18 h. MeOH (1 mL) and HCl (0.5 mL of a 6 M aqueous solution) 
were slowly added and the reaction was heated to reflux for 30 min. The reaction mixture 
was concentrated, taken up in DMSO (1 mL) and purified by MDAP (Method B). The 
appropriate fractions were combined and the solvent was evaporated under reduced pressure 
to afford 18b (4 mg, 51%) as a white solid: 1H NMR G (400 MHz, CD3OD) 7.70 (d, J = 6.0 
Hz, 1H), 7.45 (d, J = 2.0 Hz, 1H), 7.35 (d, J = 8.0 Hz, 1H), 7.27 (dd, J = 8.0, 2.0 Hz, 1H), 
5.85 (d, J = 6.0 Hz, 1H), 4.59 (s, 2H), 3.78 ± 3.63 (m, 2H), 3.60 ± 3.48 (m, 2H), 3.05 (d, J = 
12.0 Hz, 1H), 2.77 ± 2.59 (m, 3H), 2.58 ± 2.35 (m, 4H), 2.24 (dd, J = 12.0, 4.0 Hz, 1H), 1.81 
(d, J = 12.0 Hz, 1H), 1.73 ± 1.60 (m, 4H), 1.55 ± 1.37 (m, 6H), 1.18 ± 1.03 (m, 1H); the two 
exchangeable NH protons were not observed; LCMS (System B, UV, ES) RT = 1.69 min, 
[M+H]+ = 489, 491, 493, 100% purity. 
6.18 2-Chloro-N-(2,4-difluorobenzyl)pyrimidin-4-amine (19) 
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Was prepared from 12 (1.0 g, 6.7 mmol), 2,4-difluorobenzylamine (0.79 mL, 6.7 mmol) and 
DIPEA (1.8 mL, 10 mmol) according to the procedure described for the preparation of 14 to 
give 18 (1.26 g, 73%) as a white solid: 1H NMR G (400 MHz, CD3OD) 7.88 (br. s, 1H), 7.52 
± 7.34 (m, 1H), 7.03 ± 6.82 (m, 2H), 6.45 (d, J = 6.0 Hz, 1H), 4.58 (br. s, 2H); the 
exchangeable NH proton was not observed; 19F NMR G (376 MHz, CD3OD) (-112.8)-(-
113.5) (m, 1F), (-115.9)-(-116.4) (m, 1F); LCMS (System A, UV, ES) RT = 0.94 min, 
[M+H]+ = 256, 258, 100% purity. LCMS (System A, UV, ES) RT = 0.92 min, [M+H]+ = 256, 
258, 100% purity. 
6.19 tert-Butyl 8-(4-((2,4-difluorobenzyl)amino)pyrimidin-2-yl)-2,8-
diazaspiro[4.5]decane-2-carboxylate, hydrochloride salt (20) 
Was prepared from 15 (188 mg, 0.782 mmol) and 19 (200 mg, 0.782 mmol) according to the 
procedure described for the preparation of 16 to give 20 (245 mg, 63%) as a white solid: 1H 
NMR G (400 MHz, CD3OD) 7.57 (d, J = 7.0 Hz, 1H), 7.49 ± 7.33 (m, 1H), 7.05 ± 6.86 (m, 
2H), 6.12 (d, J = 7.0 Hz, 1H), 4.66 (s, 2H), 3.88 ± 3.60 (m, 4H), 3.48 ± 3.39 (m, 2H), 3.26 (s, 
2H), 1.87 (t, J = 7.0 Hz, 2H), 1.70 ± 1.59 (m, 4H), 1.47 (s, 9H); the two exchangeable protons 
were not observed; 19F NMR (376 MHz, CD3OD) (-112.5) ± (-112.8) (m, 1F), (-115.7) ± (-
116.0) (m, 1F); LCMS (System A, UV, ES) RT = 0.97 min, [M+H]+ = 460, 100% purity.  
6.20 N-(2,4-Difluorobenzyl)-2-(2,8-diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine, di-
hydrochloride salt (21) 
Was prepared from 20 (245 mg, 0.494 mmol) and HCl (3.0 mL of a 4 M solution in dioxane, 
12.0 mmol) according to the procedure described for the preparation of 17 to give 21 (213 
mg, 100%) as a colorless gum: 1H NMR G (400 MHz, CD3OD) 7.60 (d, J = 7.0 Hz, 1H), 7.51 
± 7.35 (m, 1H), 7.06 ± 6.85 (m, 2H), 6.16 (d, J = 7.0 Hz, 1H), 4.67 (s, 2H), 3.93 ± 3.82 (m, 
2H), 3.80 ± 3.70 (m, 2H), 3.45 (t, J = 7.5 Hz, 2H), 3.21 (s, 2H), 2.05 (t, J = 7.5 Hz, 2H), 1.77 
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(t, J = 5.6 Hz, 4H); the four exchangeable protons were not observed; 19F NMR G (376 MHz, 
MeOD-d4) (-112.5) ± (-112.7) (m, 1F), (-115.8) ± (-116.0) (m, 1F); LCMS (System A, UV, 
ES) RT = 0.50 min, [M+H]+ = 360, 100% purity.  
6.21 (±)-(8-(4-((2,4-Difluorobenzyl)amino)pyrimidin-2-yl)-2,8-diazaspiro[4.5]decan-2-
yl)(pyrrolidin-2-yl)methanone (22) 
Was prepared from 21 (30 mg, 0.069 mmol) and (±)-N-BOC-proline (15 mg, 0.069 mmol) 
according to the procedure described for the preparation of 11a to give 22 (19 mg, 60%) as a 
colourless gum: 1H NMR (500 MHz, CD3OD) 7.68 (d, J = 6.0 Hz, 1H), 7.44 ± 7.32 (m, 1H), 
6.97 ± 6.79 (m, 2H), 5.81 (d, J = 6.0 Hz, 1H), 4.53 (s, 2H), 3.84 ± 3.75 (m, 2H), 3.75 ± 3.64 
(m, 2H), 3.63 ± 3.43 (m, 3H), 3.41 ± 3.32 (m, 2H), 3.19 ± 3.09 (m, 1H), 2.81 ± 2.71 (m, 1H), 
2.26 ± 2.13 (m, 1H), 1.92 (t, J = 7.0 Hz, 1H), 1.87 ± 1.71 (m, 3H), 1.70 ± 1.59 (m, 1H), 1.57 ± 
1.46 (m, 4H); the two exchangeable NH protons were not observed; 13C NMR G (126 MHz, 
DMSO-d6, 393.4 K) 171.8, 161.9, 160.8, 160.0 (2C), 154.2, 129.9, 122.5, 109.9, 102.4, 93.9, 
58.2, 54.6, 46.0, 42.8, 39.9 (2C), 36.2, 33.1 (2C), 28.6, 25.1 (2 aromatic carbons missing due 
to weak signal); 19F NMR G (376 MHz, CD3OD) (-113.5) ± (-115.3) (m, 1F), (-116.0) ± (-
117.9) (m, 1F); Anal. Calcd. for C24H31F2N6O = 457.2522. Found = 457.2515; [M+H]+; 
LCMS (System A, UV, ES) RT = 0.54 min, [M+H]+ = 457, 100% purity. 
6.22 (±)-N-(2,4-Difluorobenzyl)-2-(2-(pyrrolidin-2-ylmethyl)-2,8-
diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine (23) 
A mixture of 21 (free base) (36 mg, 0.10 mmol) and 1-BOC-2-formylpyrrolidine (20 mg, 
0.10 mmol) in THF (1 mL) was treated with 4A molecular sieves (20 mg) and sodium 
triacetoxyborohydride (25.5 mg, 0.12 mmol) and the mixture was stirred at 25 °C overnight 
under nitrogen.  The reaction mixture was filtered through celite and the filtrate was 
concentrated under reduced pressure.  TFA (0.5 mL) was added to the residue and the 
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reaction stirred at room temperature for 30min, and then concentrated under reduced 
pressure.  The residue was purified by MDAP (Method A) appropriate fractions were 
evaporated under reduced pressure and the residue was dissolved in MeOH and applied to an 
aminopropyl cartridge (1g). The cartridge was washed with MeOH and the solution was 
concentrated under nitrigen in a blow-down unit.  The concentrate was freeze-dried to give 
23 (20 mg, 45%) as a beige coloured solid: 1H NMR (400 MHz, CD3OD) 7.68 (d, J = 6.0 Hz, 
1H), 7.45 ± 7.32 (m, 1H), 7.00 ± 6.80 (m, 2H), 5.81 (d, J = 6.0 Hz, 1H), 4.55 (s, 2H), 3.80 ± 
3.67 (m, 2H), 3.66 ± 3.55 (m, 2H), 3.28 ± 3.14 (m, 1H), 3.05 ± 2.94 (m, 1H), 2.85 (td, J = 
10.0, 7.0 Hz, 1H), 2.77 ± 2.37 (m, 6H), 2.06 ± 1.90 (m, 1H), 1.86 ± 1.75 (m, 2H), 1.71 (t, J = 
7.0 Hz, 2H), 1.58 ± 1.46 (m, 4H), 1.46 ± 1.37 (m, 1H); the two exchangeable NH protons 
were not observed; LCMS (System B, UV, ES) RT = 1.45 min, [M+H]+ = 443, 99% purity. 
6.23 2-Chloro-N-(2,4-dichlorobenzyl)-N-methylpyrimidin-4-amine (24) 
Prepared from 12 (0.50 g, 3.4 mmol), N-methyl-(2,4-dichlorobenzyl)amine (0.64 g, 3.4 
mmol) and DIPEA (1.3 mL, 7.4 mmol) according to the procedure described for the 
preparation of 14 to give 24 (0.39 g, 38%) as a white solid: 1H NMR G (400 MHz, CD3OD) 
8.04 (br. s, 1H), 7.52 (d, J = 2.0 Hz, 1H), 7.31 (dd, J = 8.0, 2.0 Hz, 1H), 7.12 (d, J = 8.0 Hz, 
1H), 6.66 (br. s, 1H), 4.89 (s, 2H (obscured by HOCD3), 3.13 (br. s, 3H); LCMS (System A, 
UV, ES) RT = 1.28 min, [M+H]+ = 302, 304, 306, 100% purity.  
6.24 N-(2,4-Dichlorobenzyl)-N-methyl-2-(2,8-diazaspiro[4.5]decan-8-yl)pyrimidin-4-
amine (25)  
A mixture of 24 (200 mg, 0.661 mmol), 15 (159 mg, 0.661 mmol) and isopropyl alcohol (1 
mL) were stirred at 90 °C for 24 h. The reaction was cooled to ambient temperature, 
concentrated under reduced pressure and treated with HCl (1.0 mL of a 4 M solution in 
dioxane, 4.0 mmol). The reaction was stirred at ambient temperature for 30 min and was then 
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partitioned between EtOAc (30 mL) and saturated aqueous sodium bicarbonate solution (30 
mL). The organic layer was separated, dried using a hydrophobic frit and concentrated under 
reduced pressure to give 25 (180 mg, 67%) as a pale brown oil: 1H NMR G (400 MHz, 
CD3OD) 7.86 (d, J = 6.0 Hz, 1H), 7.49 (d, J = 2.0 Hz, 1H), 7.28 (dd, J = 8.0, 2.0 Hz, 1H), 
7.07 (d, J = 8.0 Hz, 1H), 6.00 (d, J = 6.0 Hz, 1H), 4.84 (br. s, 2H), 3.81 ± 3.66 (m, 2H), 3.65 
± 3.52 (m, 2H), 3.14 (s, 3H), 2.98 (t, J = 7.0 Hz, 2H), 2.72 (s, 2H), 1.76 ± 1.59 (m, 2H), 1.53 
± 1.39 (m, 4H); the exchangeable NH proton was not observed; LCMS (System B, UV, ES) 
RT = 1.82 min, [M+H]+ = 407, 409, 411, 87% purity. 
 
6.25 (±)-(8-(4-((2,4-Dichlorobenzyl)(methyl)amino)pyrimidin-2-yl)-2,8-
diazaspiro[4.5]decan-2-yl)(pyrrolidin-2-yl)methanone (26) 
Was prepared from 25 (94 mg, 0.23 mmol) and (±)-N-BOC-proline (50 mg, 0.23 mmol) 
according to the procedure described for the preparation of 11a to give 26 (31 mg, 26%) as a 
colourless gum: 1H NMR G (400 MHz, CD3OD) 7.87 (d, J = 6.0 Hz, 1H), 7.49 (t, J = 2.0 Hz, 
1H), 7.27 (dd, J = 8.0, 2.0 Hz, 1H), 7.06 (d, J = 8.0 Hz, 1H), 6.01 (d, J = 6.0 Hz, 1H), 4.84 
(br. s, 2H), 3.89 ± 3.43 (m, 8H), 3.23 ± 3.08 (m, 4H), 2.88 ± 2.72 (m, 1H), 2.28 - 2.11 (m, 
1H), 1.91 (t, J = 7.0 Hz, 1H), 1.88 ± 1.73 (m, 3H), 1.73 ± 1.59 (m, 2H), 1.49 (br. s, 4H); the 
exchangeable NH proton was not observed; LCMS (System B, UV, ES) RT = 1.86 min, 
[M+H]+ = 503, 505, 507, 100% purity. 
6.26 (±)-N-(2,4-Dichlorobenzyl)-N-methyl-2-(2-(pyrrolidin-2-ylmethyl)-2,8-
diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine (27) 
Was prepared from 25 (90 mg, 0.22 mmol) and (±)-N-BOC-2-formylpyrrolidine (44 mg, 0.22 
mmol) according to the procedure described for the preparation of 23 to give 27 (35 mg, 
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32%) as a white solid: 1H NMR G (400 MHz, CD3OD) 7.85 (d, J = 6.0 Hz, 1H), 7.49 (d, J = 
2.0 Hz, 1H), 7.27 (dd, J = 8.0, 2.0 Hz, 1H), 7.06 (d, J = 8.0 Hz, 1H), 5.99 (d, J = 6.0 Hz, 1H), 
4.83 (br. s, 2H), 3.74 ± 3.49 (m, 4H), 3.30 ± 3.19 (m, 1H), 3.13 (s, 3H), 3.01 (td, J = 10.0, 7.0 
Hz, 1H), 2.87 (td, J = 10.0, 7.0 Hz, 1H), 2.77 ± 2.67 (m, 1H), 2.67 ± 2.35 (m, 5H), 2.03 ± 
1.92 (m, 1H), 1.88 ± 1.76 (m, 2H), 1.69 (t, J = 7.0 Hz, 2H), 1.55 ± 1.35 (m, 5H); the 
exchangeable NH proton was not observed; LCMS (System B, UV, ES) RT = 1.72 min, 
[M+H]+ = 489, 491, 493, 100% purity. 
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Table 1.  In vitro data pKi for [125I]-TARC binding assay, calculated logP, measured chrom 
logD at pH 7.4, CLND solubility and human whole blood actin polymerisation assay pA2. 
Cmpd [125I]-TARC 
pKi 
± SEM 
(n) 
clogP Chrom 
logD 
CLNDa 
Solub. 
(Pg/mL) 
hWB 
pA2 
1 8.6±0.1 
(3) 
4.5 3.5 140 6.76±0.03 
(80) 
9 
 
8.5±0.1 
(8) 
4.4 2.9 193 6.6±0.1 
(24) 
17. 2HCl 6.5±0.1 
(2) 
4.0 3.5 144 ND 
(±)-11a 7.6±0.1 
(4) 
3.8 3.5 79 ND 
(R)-11a 7.8±0.3 
(8) 
3.8 3.4 180 ND 
(S)-11a 7.0±0.4 
(4) 
3.8 3.3 165 ND 
(R)-11b 7.6±0.3 
(4) 
4.3 3.7 172 ND 
(S)-11b 7.7±0.2 
(4) 
4.3 3.7 170 ND 
(±)-11c.TFA 7.3±0.2 
(2) 
3.3 3.3 339 ND 
(±)-11d 7.3±0.2 3.3 3.5 186 ND 
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(2) 
11e.2TFA 6.9±0.2 
(2) 
3.1 3.2 138 ND 
11f 6.2±0.1 
(2) 
5.0 7.2 3 ND 
11g 7.0±0.1 
(2) 
3.7 5.3 17 ND 
(±)-11h ND 3.4 3.8 233 ND 
(±)-18a 8.8±0.5 
(4) 
4.3 4.4 270 6.7±0.3 
(2) 
(S)-18a 8.4±0.2 
(4) 
4.3 4.3 56 ND 
(R)-18a 8.3±0.1 
(4) 
4.3 4.2 16 ND 
(±)-18b 8.6±0.1 
(2) 
4.9 4.6 182 ND 
(±)-22 7.6±0.1 
(2) 
2.6 2.9 175 ND 
(±)-23 8.5±0.3 
(5) 
3.2 3.2 160 ND 
(±)-26 7.6±0.2 
(2) 
4.2 4.5 190 ND 
(±)-27 9.0±0.2 
(5) 
4.7 5.3 141 6.0±0.2 
(2) 
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Table 2.  The effectiveness of (R)-18a, (S)-18a, (±)-23 and (±)-27 to internalise the CCR4 
receptor, and the percentage reduction in expression of cell-surface receptors.  
Cmpd pEC50 
% of CCR4 
receptors  
internalised 
CCL22 8.8 ± 0.1 (n=5) 98 ± 7 
(S)-18a 7.9 ± 0.2 (n=5) 56 ± 10 
(R)-18a 8.2 ± 0.2 (n=5) 64 ± 10 
(±)-23 7.8 ± 0.2 (n=5) 62 ± 4 
(±)-27 6.8 ± 0.2 (n=5) 74 ± 6 
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